FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)

View source ↗

Summary

The FDA approved a supplemental application for NEURACEQ (FLORBETABEN F 18) submitted by Lantheus Biosciences Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• NEURACEQ (Florbetaben F 18)

Snippet

SUPPL AP for NEURACEQ (FLORBETABEN F 18)